Conditions: Eosinophilic Asthma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 464
Healthy volunteers: no

Brief summary:
The primary objective of this study is to determine whether reslizumab is more effective than placebo in reducing the number of clinical asthma exacerbations (CAEs) in patients with eosinophilic asthma.

Detailed description:

Arms:
arm 1: Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses. arm 2: Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.

Interventions: intervention 1: Reslizumab intervention 2: Placebo
Intervention descriptions: intervention 1: Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses. intervention 2: Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks for a total of 13 doses.

Protocol document: